TrialBlood neoplasia2025
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.
Tadeusz Kubicki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this paperpooled itcites it